Ticker Symbol: TOS/TSX
Shares Outstanding: 46 244 102
QUEBEC CITY, Sept. 28 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TOS/TSX)
announces the sale of a second 125L Ozone Sterilizer to a Canadian hospital
that was among the first to utilize the device. The acquisition of a second
ozone sterilizer allows this hospital to completely discontinue the use of
Ethylene Oxide within its facility.
This hospital is among the most renowned in Cardiology and has achieved
numerous firsts, both internationally and within Canada. One can find under
the same roof renowned specialists, expertise and leading-edge technology
focused in strategic areas such as surgery, hemodynamics, specialized cardiac
care, electrophysiology and nuclear medicine.
"This hospital provides TSO3 both visibility and credibility with other
hospitals specializing in cardiology, since it compares favourably with
leading facilities in that field, in the United States as well as in Europe",
said Jocelyn Vézina, CEO for TSO3 Inc. "This second sale to an existing
customer is another positive step for TSO3, as it highlights that current
users are satisfied with the benefits and advantages of integrating ozone
sterilization into their hospitals. Of course, the introduction of a new
technology in the medical sector is a long and rigorous process, but the base
of satisfied customers that we are currently building will ensure our growth."
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods the ozone sterilization process developed
and patented by TSO3 meets all standards required by the evolution in
sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 65 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3